SciELO - Scientific Electronic Library Online

 
vol.128 número8Presencia de integrones y su relación con la resistencia a cefalosporinas de tercera generación en cepas de Acinetobacter baumannii de origen nosocomialUtilidad de la cintigrafía de glándulas salivales en el síndrome de Sjögren y su relación con el resultado de la biopsia de labio.: Estudio comparativo con una población control índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

Compartir


Revista médica de Chile

versión impresa ISSN 0034-9887

Resumen

DEVOTO C, Enzo; ARAVENA C, Lucía  y  RIOS S, Rafael. Treatment of hirsutism with spironolactone and with spironolactone plus dexamethasone. Rev. méd. Chile [online]. 2000, vol.128, n.8, pp.868-875. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872000000800006.

Background: Spironolactone has an anti androgenic effect, inhibiting the binding of androgens to their receptor. This antagonistic effect is the basis for the use of spironolactone in the treatment of hirsutism. Aim: To study the effectiveness and safety of spironolactone in the treatment of hirsute women and of the association of spironolactone plus dexamethasone in the treatment of hirsutism with glucocorticoid sensitive hyperandrogenism. Patients and method: Sixteen women (group 1) with peripheral hirsutism (defined as those with normal androgens levels, normal menstrual cycles and ovulation) and 24 women (group 2) with glucocorticoid sensitive hyperandrogenic hirsutism were studied. Group 1 was treated with spironolactone 50 mg bid and group 2 with same spironolactone dose plus dexamethasone 0.5 mg at 23 h during one month and 0.25 mg thereafter. Patients were followed during one year. Results: After one year of treatment, a 54% reduction in Moncada hirsutism escore was observed in group 1 and 52% reduction in group 2. Observed secondary effects of spironolactone were increases in diuresis, fatigability, acne aggravation and seborrhea in two patients. Two additional patients had spotting. No secondary effect attributable to glucocorticoid use were observed. Conclusions: Spironolactone is effective and safe in the treatment of hirsutism. Androgenic supression did no increases its effectiveness, underscoring the peripheral anti androgenic activity os spironolactone. (Rev Méd Chile 2000; 128: 868-75).

Palabras clave : Dexamethasone; Hirsutism; Hyperandrogenism; spironolactone.

        · texto en Español

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons